December 2025 in “Journal of health economics and outcomes research” Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
September 2017 in “Journal of Investigative Dermatology” Injections of special skin cells showed potential in treating hair loss, with some participants experiencing increased hair density.
May 2018 in “Hair transplant forum international” The document's conclusion cannot be summarized because the content is not accessible or understandable.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
39 citations
,
August 1998 in “FEBS Letters” Two new enzymes, PAD-R11 and PAD-R4, were cloned and showed activity, with PAD-R11 resembling epidermal enzymes.
7 citations
,
January 2015 in “Biological & Pharmaceutical Bulletin” Rice Bran Supercritical CO2 Extract significantly increased hair density and diameter in male alopecia patients without any side effects.
January 2025 in “Frontiers in Immunology” IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.
September 2023 in “Journal of the American Academy of Dermatology”
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
1 citations
,
December 2024 in “Journal of Orthopaedic Research®” Aromoline and DRD4 are potential targets for osteoarthritis treatment.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
1 citations
,
November 2023 in “Skin Appendage Disorders” 308 nm excimer lamp therapy is effective for alopecia areata but less so for severe cases.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
January 2024 in “Wiadomości Lekarskie” AI and advanced technologies are improving medical diagnostics and treatments.
September 2025 in “The Open Dermatology Journal” The AI showed high accuracy in diagnosing skin conditions but needs improvement for immunological and infectious disorders.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
January 2023 in “Pakistan Armed Forces Medical Journal” 2 citations
,
July 2025 in “Analytical Chemistry” The method effectively images and correlates elements and metabolites in tissue samples at a micron scale.
April 2025 in “The Egyptian Journal of Surgery” The SASJ bypass is a safe and effective surgery for weight loss and improving health conditions.
March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
Blocking the Mitochondrial Pyruvate Carrier causes stress in hair follicles, which can be reduced by an ISR inhibitor.